價(jià)格 | ¥8400 | ¥16980 |
包裝 | 5mg | 25mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:化合物 T22633 | 英文名稱:CCT251545 analogue, Compound 51 |
品牌: TargetMol | 產(chǎn)地: 美國(guó) |
保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T22633 |
名稱 | CCT251545 analogue, Compound 51 |
描述 | CCT251545 analog is a potent and selective CDK8/19 inhibitor (IC50: 5.1 nM and 5.6 nM, respectively). Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. CDK8 plays as an oncogene in gastric and colorectal cancers through the activation of WNT signaling. |
體外活性 | In SW620 human colorectal carcinoma cells harbouring activating APC-mutation, Compound 51 inhibited phospho-STAT1SER727 ( IC50 :17.9 nM). It is a biomarker of CDK8 inhibition [1]. |
體內(nèi)活性 | In vivo mouse and rat PK experiments, The compound demonstrated medium in vivo clearance and Vd but low bioavailability in mice. In an SW620 colorectal carcinoma human tumor xenograft model, Compound 51 (5 mg/kg p.o. dose) inhibited phospho-STAT1SER727 in a time-dependent way. Compound 51 is an advanced chemical tool to further explore the efficacy, safety, and tolerability of dual CDK8/19 ligands [1]. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : > 20.7 mg/mL, Heating is recommended. |
關(guān)鍵字 | CCT251545 analogue, Compound 51 | CCT-251545 analogue, Compound 51 |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 589.8595萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
詢價(jià) |
VIP1年
|
青島愷潤(rùn)生物醫(yī)藥科技有限公司
|
2024-11-02 | |
¥198 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2024-12-02 |